Development of first-of-its-kind therapeutic approach to treat carcinoid syndrome diarrhea creates highly lucrative growth opportunities for market players. However, low awareness and certain side effects associated with this therapy are expected to hinder growth of the carcinoid syndrome diarrhea treatment market.
Increasing prevalence of rare carcinoid syndrome diarrhea to boost market growth
According to the National Organization for Rare Disorders( NORD), 2017, each year, only 27 individuals per million population are estimated to be diagnosed with carcinoid tumors in the U. S., amongst whom, only 10 % individuals develop carcinoid syndrome. Moreover, it affects both males and females in equal number. Increasing prevalence of the disease is in turn, increasing demand for carcinoid syndrome diarrhea treatment devices. This in turn is expected to fuel growth of the carcinoid syndrome diarrhea treatment market.
Browse Complete Report For More Information https:// www. coherentmarketinsights. com / ongoing-insight / carcinoid-syndrome-diarrhea-treatmentmarket-1216
Major key players operating in the carcinoid syndrome diarrhea treatment market include Lexicon Pharmaceuticals, Inc., Novartis International AG(Sa( Sandoz), P�), Pharmascience Inc., Omega Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Mylan N. V., I�., Ipsen Biopharmaceuticals, Inc., Sirtex Medical Limited, and BTG(Sa International Ltd.
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us Mr. Shah Coherent Market Insights 1001 4th Ave, # 3200 Seattle, WA 98154 Tel: + 1-206-701-6702 Email: sales @ coherentmarketinsights. com
@